Osteocalcin levels decrease during the treatment of an acute
depressive episode

J 2022

Osteocalcin levels decrease during the treatment of an acute depressive episode

BARTEČKŮ, Elis, Jana HOŘÍNKOVÁ, Pavel KŘENEK, Alena DAMBORSKÁ, Josef TOMANDL et. al.

Základní údaje

Originální název

Osteocalcin levels decrease during the treatment of an acute depressive episode

Autoři

BARTEČKŮ, Elis (203 Česká republika, domácí), Jana HOŘÍNKOVÁ (203 Česká republika, garant, domácí), Pavel KŘENEK (203 Česká republika, domácí), Alena DAMBORSKÁ (203 Česká republika, domácí), Josef TOMANDL (203 Česká republika, domácí), Marie TOMANDLOVÁ (203 Česká republika, domácí), Jan KUČERA (203 Česká republika, domácí), Jana KUČEROVÁ (203 Česká republika, domácí) a Julie DOBROVOLNÁ (203 Česká republika, domácí)

Vydání

Frontiers in Psychiatry, LAUSANNE, FRONTIERS MEDIA SA, 2022, 1664-0640

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30215 Psychiatry

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.700

Kód RIV

RIV/00216224:14110/22:00126850

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3389/fpsyt.2022.893012

UT WoS

000841615400001

Klíčová slova anglicky

osteocalcin; major depressive disorder; biomarker; depression; antidepressant treatment

Štítky

14110222, 14110512, 14110518, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 1. 2023 08:11, Mgr. Tereza Miškechová

Anotace

V originále

ObjectivesOsteocalcin is a protein secreted by osteoblasts with a versatile endocrine role. Several domains in which it plays a role-stress response, monoamine synthesis, and cognitive functioning-are implicated also in the pathophysiology of major depressive disorder. In search of possible objective biomarkers of depression, the aim of the study was to assess the relationship between osteocalcin and depressive symptoms during the treatment of depressive episode. MethodsThe study included female inpatients with at least moderate depressive episode. In these patients, depression severity was measured using the Montgomery-angstrom sberg Depression Rating Scale (MADRS), and osteocalcin levels were assessed before the stabilization of antidepressive treatment and after 6 weeks. Relationships between osteocalcin levels and symptoms were analyzed with mixed-effect and linear models, taking into account age, menopausal status, and body mass index. ResultsIn 11 out of 13 enrolled inpatients, osteocalcin levels decreased during the first 6 weeks of treatment; this decrease was significant according to the mixed-effects model (t = -2.345, p = 0.019). According to the linear model, this decrease was significantly associated with reduction in depressive symptom severity (t = 2.673, p = 0.028). Osteocalcin was not associated with initial depressive symptom severity, and initial osteocalcin levels did not predict response to treatment. Limitations of the study include low sample size and inclusion of both pre- and postmenopausal women of various ages. ConclusionsThis preliminary study suggests that osteocalcin may be a candidate biomarker of antidepressive treatment response and that this topic warrants further investigation.

Návaznosti

EF15_003/0000469, projekt VaV

Název: Cetocoen Plus

EF17_043/0009632, projekt VaV

Název: CETOCOEN Excellence

LM2018121, projekt VaV

Název: Výzkumná infrastruktura RECETOX (Akronym: RECETOX RI)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, RECETOX RI

857560, interní kód MU
(Kód CEP: EF17_043/0009632)

Název: CETOCOEN Excellence (Akronym: CETOCOEN Excellence)

Investor: Evropská unie, CETOCOEN Excellence, Spreading excellence and widening participation

Přiložené soubory

2223869.pdf

Vyhledat podobné dokumenty

Citovat

BARTEČKŮ, Elis, Jana HOŘÍNKOVÁ, Pavel KŘENEK, Alena DAMBORSKÁ, Josef TOMANDL, Marie TOMANDLOVÁ, Jan KUČERA, Jana KUČEROVÁ a Julie DOBROVOLNÁ. Osteocalcin levels decrease during the treatment of an acute depressive episode. Frontiers in Psychiatry. LAUSANNE: FRONTIERS MEDIA SA, 2022, roč. 13, August 2022, s. 1-8. ISSN 1664-0640. Dostupné z: https://dx.doi.org/10.3389/fpsyt.2022.893012.

@article{2223869,
   author = {Bartečků, Elis and Hořínková, Jana and Křenek, Pavel and Damborská, Alena and Tomandl, Josef and Tomandlová, Marie and Kučera, Jan and Kučerová, Jana and Dobrovolná, Julie},
   article_location = {LAUSANNE},
   article_number = {August 2022},
   doi = {http://dx.doi.org/10.3389/fpsyt.2022.893012},
   keywords = {osteocalcin; major depressive disorder; biomarker; depression; antidepressant treatment},
   language = {eng},
   issn = {1664-0640},
   journal = {Frontiers in Psychiatry},
   title = {Osteocalcin levels decrease during the treatment of an acute depressive episode},
   url = {https://www.frontiersin.org/articles/10.3389/fpsyt.2022.893012/full},
   volume = {13},
   year = {2022}
}

TY  - JOUR
ID  - 2223869
AU  - Bartečků, Elis - Hořínková, Jana - Křenek, Pavel - Damborská, Alena - Tomandl, Josef - Tomandlová, Marie - Kučera, Jan - Kučerová, Jana - Dobrovolná, Julie
PY  - 2022
TI  - Osteocalcin levels decrease during the treatment of an acute depressive episode
JF  - Frontiers in Psychiatry
VL  - 13
IS  - August 2022
SP  - 1-8
EP  - 1-8
PB  - FRONTIERS MEDIA SA
SN  - 16640640
KW  - osteocalcin
KW  - major depressive disorder
KW  - biomarker
KW  - depression
KW  - antidepressant treatment
UR  - https://www.frontiersin.org/articles/10.3389/fpsyt.2022.893012/full
N2  - ObjectivesOsteocalcin is a protein secreted by osteoblasts with a versatile endocrine role. Several domains in which it plays a role-stress response, monoamine synthesis, and cognitive functioning-are implicated also in the pathophysiology of major depressive disorder. In search of possible objective biomarkers of depression, the aim of the study was to assess the relationship between osteocalcin and depressive symptoms during the treatment of depressive episode. MethodsThe study included female inpatients with at least moderate depressive episode. In these patients, depression severity was measured using the Montgomery-angstrom sberg Depression Rating Scale (MADRS), and osteocalcin levels were assessed before the stabilization of antidepressive treatment and after 6 weeks. Relationships between osteocalcin levels and symptoms were analyzed with mixed-effect and linear models, taking into account age, menopausal status, and body mass index. ResultsIn 11 out of 13 enrolled inpatients, osteocalcin levels decreased during the first 6 weeks of treatment; this decrease was significant according to the mixed-effects model (t = -2.345, p = 0.019). According to the linear model, this decrease was significantly associated with reduction in depressive symptom severity (t = 2.673, p = 0.028). Osteocalcin was not associated with initial depressive symptom severity, and initial osteocalcin levels did not predict response to treatment. Limitations of the study include low sample size and inclusion of both pre- and postmenopausal women of various ages. ConclusionsThis preliminary study suggests that osteocalcin may be a candidate biomarker of antidepressive treatment response and that this topic warrants further investigation.
ER  -

BARTEČKŮ, Elis, Jana HOŘÍNKOVÁ, Pavel KŘENEK, Alena DAMBORSKÁ, Josef TOMANDL, Marie TOMANDLOVÁ, Jan KUČERA, Jana KUČEROVÁ a Julie DOBROVOLNÁ. Osteocalcin levels decrease during the treatment of an acute depressive episode. \textit{Frontiers in Psychiatry}. LAUSANNE: FRONTIERS MEDIA SA, 2022, roč.~13, August 2022, s.~1-8. ISSN~1664-0640. Dostupné z: https://dx.doi.org/10.3389/fpsyt.2022.893012.

Podrobný výpis o publikaci